Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Auto-Allo SCT for Poor Risk Lymphoma
NCT01181271Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2010
- Primary completion
- Feb 2014
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous peripheral blood stem cell transplantation in diffuse large B-cell lymphoma (DLBCL), T-cell lymphoma, mantle cell lymphoma (MCL), Hodgkin lymphoma (HL), chronic lymphocytic leukemia (CLL), sponsored by Massachusetts General Hospital. Started Aug 2010; status: completed.
02
Drugs
autologous peripheral blood stem cell transplantation
03
Conditions
diffuse large B-cell lymphoma (DLBCL)T-cell lymphomamantle cell lymphoma (MCL)Hodgkin lymphoma (HL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01181271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01181271.